hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study

• DOI: 10.3389/fneur.2022.1073476
• Publication Date: 2023-01-11T06:15:49Z
• Authors: Melanie Casile; Judith Passildas; Bérengère Vire; Ioana Molnar; Xavier Durando
• Keywords: brain cancer; 0303 health sciences; hPG80; Progastrin; [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology; [SDV.CAN]Life Sciences [q-bio]/Cancer; Biomarker; Brain cancer; 3. Good health; High-grade Glial Tumors; 03 medical and health sciences; progastrin; Neurology; biomarker; Neurology (clinical); Neurology. Diseases of the nervous system; RC346-429; high grade glial tumors

Currently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor there are no biomarkers. hPG80 (circulating progastrin) secreted into blood by tumor cells has been widely studied in colorectal cancer. Its involvement tumorigenesis demonstrated literature. Moreover, according to a recent study, is expressed cancer at significantly higher concentration than control group composed healthy donors.The PROGLIO study pilot, single-center, longitudinal that primarily seeks evaluate circulating plasma concentrations over time tumors. A fasting sample will be taken on start end day radiotherapy during adjuvant chemotherapy (every 3 cycles). Follow-up monitoring performed for 9 months, every months follow-up MRI. The plans recruit 30 recruitment started February 2022.ClinicalTrials.gov, ID NCT05157594; registered October 27, 2021.